Dendritic cell–derived exosomes for cancer therapy
Jonathan M. Pitt, Fabrice André, Sebastian Amigorena, Jean-Charles Soria, Alexander Eggermont, Guido Kroemer, Laurence Zitvogel

To cite this version:
Jonathan M. Pitt, Fabrice André, Sebastian Amigorena, Jean-Charles Soria, Alexander Eggermont, et al.. Dendritic cell–derived exosomes for cancer therapy. Journal of Clinical Investigation, American Society for Clinical Investigation, 2016, 126 (4), pp.1224-1232. 10.1172/JCI81137. hal-01310534

HAL Id: hal-01310534
https://hal.sorbonne-universite.fr/hal-01310534
Submitted on 2 May 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Dendritic cell–derived exosomes for cancer therapy

Jonathan M. Pitt,1,2,3 Fabrice André,1,3,4,5 Sebastian Amigorena,6 Jean-Charles Soria,1,3,4,7 Alexander Eggermont,1 Guido Kroemer,8,9,10,11,12,13,14,15 and Laurence Zitvogel1,2,3,4,5

Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France. 1INSERM Unit U1015, Villejuif, France. 2Université Paris Sud, Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France. 3INSERM Unit U981, Villejuif, France. 4Department of Medical Oncology, Villejuif, France. 5INSERM Unit U932, Institut Curie, Paris, France. 6Drug Development Department (DITEP), Villejuif, France. 7INSERM U848, Villejuif, France. 8Metabolomics Platform, GRCC, Villejuif, France. 9Équipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, INSERM U9138, Paris, France. 10Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France. 11Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 12Université Pierre et Marie Curie, Paris, France. 13Karolinska Institute, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, Sweden.

Introduction

As the sentinel antigen-presenting cells (APCs) of the immune system, DCs play a central role in initiating antigen-specific immunity and tolerance (1). In cancer, DCs act as the initial link between oncogenesis and the host immune system, the first step of a cancer/immunity cycle that aims to eliminate cancer cells through the activation of T cells (2). Tumor-proximal DCs can capture neo-antigens created and released during oncogenesis, which the DCs subsequently process and present to cognate T cells to generate antitumor T cell responses. However, such T cell responses can only be generated if certain additional conditions are met in the local environment (2). These conditions consist of locally present immunogenic signals, such as proinflammatory cytokines, danger-associated molecular patterns (DAMPs), or pathogen-associated molecular patterns (PAMPs). Such signals trigger DCs to present captured tumor-associated antigens (TAAAs) via MHC class I (MHC-I) and MHC-II molecules to T cells in cooperation with costimulatory molecules such as CD80 and CD86, resulting in the priming and activation of TAA-specific effector T cells.

Therapies harnessing these properties of DCs to generate immune responses against tumors have great potential, though clinical progress of this application remains in its infancy. One notable exception is the success of the immunotherapy sipuleucel-T for early-stage, hormone-refractory prostate cancer. Sipuleucel-T is composed of autologous peripheral blood mononuclear cells (PBMCs) including APCs (such as DCs and their precursors) that have been stimulated ex vivo with a fusion protein consisting of the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), which drives DC differentiation and activation, combined with a prostate antigen (3). Nonetheless, DC-based immunotherapy is challenging to practice in clinical settings. Implementing such therapies across large populations is costly, requires dedicated expertise, and requires monitoring of well-defined quality control parameters. Furthermore, it is difficult to store DCs over long periods of time while maintaining their efficacy (4).

The use of DC-derived exosomes (Dex) has been heralded as a solution to many of the technical challenges associated with DC-based immunotherapy (see Table 1) because they maintain the essential immunostimulatory faculties of DCs (e.g., sharing the ability to present antigens to T cells), while the stable nature of exosomal membranes allows their frozen storage for at least 6 months (5). As biologics, Dex are also more amenable to a strictly regulated and monitored manufacturing process (e.g., their composition and MHC-I and MHC-II content can be easily defined), and they lack the risks associated with viable cellular or viral therapies such as the risk of in vivo replication (6). Finally, treatment with cell-free Dex may be more resistant to immunomodulatory events that occur in tumors than other anticancer vaccines; such events can downregulate costimulatory molecules on DCs and impede stimulation of T cell responses (7).

As discussed in detail in other sections of this review series, DCs are one of the many cell types able to secrete membrane vesicles, such as exosomes, into the extracellular environment. This manner of signaling can modulate recipient cells, such as immune cells or cancer cells, to a level beyond classical ligand/receptor signaling pathways and can create complex cellular modifications that may play a substantial role in how tumor development or immune responses proceed. Moreover, detection of circulating cancer cell–derived exosomes can serve as a noninvasive diagnostic and screening tool to detect early stages of cancer, facilitating...